The breakthrough behind Can-C and the introduction of n-acetylcarnosine eye drops took place in the early 1990s, with landmark research by the bio-physicist Dr Mark Babizhayev
and a Russian research team.
Human trials on cataract sufferers, involving a twice daily dose of NAC formulated drops over a period of six months, produced remarkable results.
The research revealed that:
•88.9 per cent of patients had improved glare sensitivity (which is a general decline in the sharpness of objects and surroundings -things literally becoming a bit fuzzy around the edges);
•90 per cent reported improved visual acuity - clearer and sharper vision;
•Perhaps most significantly, in that cataracts are characterised by a clouding of the eye lens, 41 per cent of patients experienced a significant improvement in lens 'transmissivity'.
And while the patients were taking the NAC carnosine eye drops, Dr Babizhayev
noted that there was no recurrence of cataract development.
further reported that drug tolerance was good - there were no side effects, based on the dosage of 1% NAC.
Can-C's formula is the one perfected and patented by Dr Babizhayev
team - who tried, tested and rejected many other forms of carnosine during their extensive research.
It is Dr. Babizhayev's
assertion that certain substances, including vitamins A and E inhibit the conversion process of the NAC into L-carnosine INSIDE the aqueous humor of the eye.
does not endorse them - rather the opposite (at least when used topically, however if vitamin A or E are taken orally there is no contraindication).
Can-C eye-drops have been recommended by the inventors (IVP) and Dr. Mark Babizhayev
has suggested that it is a useful adjunct in the condition of open angle glaucoma.
Extensive research by Can-C pioneer Dr. Mark Babizhayev, respected for his work at the Helmoltz Research Institute for Eye Diseases in Moscow, began in 1991.
Commenting on the research, Dr. Babizhayev
said: "For most patients treated, drug tolerance was good and no side effects were specifically associated with the application of 1 percent NAC.